• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Cigna Ventures | Health Care Venture Capital

Cigna Ventures | Health Care Venture Capital

  • Strategy
  • Partners
  • Team
  • Case Studies
  • News
  • Contact

Zerigo Health Announces Release of Eczema Solution

September 15, 2022

Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, today announced the launch of a new software release which includes integration of the American Academy of Dermatology Guideline protocols for the treatment of eczema with narrowband ultraviolet B (NB-UVB) phototherapy.

Evernorth, Cigna Corporation’s health services business, is the first to launch Zerigo’s solution for both psoriasis and eczema, which will be offered as a pilot program through its Digital Health Formulary. The Evernorth Digital Health Formulary connects employers, insurers and patients with innovative, affordable, and evidence-based care that meets their broader health care needs. The pilot program will enable more people with chronic skin conditions to better manage their conditions.

SEE FULL ARTICLE

Filed Under: News

Primary Sidebar

Categories

  • News
  • Partnership Activity

More news

  • Evernorth’s New Behavioral Care Practice Offers Quality Care To Improve Mental Well-Being March 13, 2024
  • 9amHealth Raises $9.5M Series A Extension Led by The Cigna Group Ventures to Expand to Employers Nationwide February 20, 2024
  • Prognos Health Raises $23 Million May 11, 2023
  • Monogram Health’s In-Home Services Now Available to More Older Adults Living with Chronic Kidney Conditions February 7, 2023
  • NOCD Completes Additional Funding in its Quest to End the OCD Crisis January 31, 2023
  • Monogram Health Closes $375M Growth Capital Raise to Support Continued Expansion of Innovative In-Home Kidney and Polychronic Care Model January 13, 2023
  • Valera Health Announces $45 Million Growth Equity Financing to Increase Access to Evidence-based Mental Health Services for High Acuity Patients October 31, 2022

Footer

  • Strategy
  • Partners
  • Team
  • Case Studies
  • News
  • Contact

By contacting The Cigna Group Ventures through this website, you agree and acknowledge that information you submit will not be considered or treated as confidential or proprietary unless and until a separate agreement is signed and that The Cigna Group Ventures and its affiliates are under no obligation to review your submission or to enter into any agreement, investment or transaction associated with the submission. In no event will The Cigna Group Ventures or any of its affiliates be limited in, or restricted from, the pursuit of any opportunities, either alone or with third parties.

The information contained herein does not constitute a distribution, an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction in which such distribution or offer is not authorized. In particular, the information herein is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States (U.S.) or for the benefit of any U.S. person (being residents of the United States or partnerships or corporations organized under the laws of the United States), nor in any other country.

The Cigna Group name, logo and other marks are owned by Cigna Intellectual Property, Inc.
Privacy Policy | Terms of Use | Accessibility | Cookie Settings
© 2024 The Cigna Group Ventures. All rights reserved.

This site is protected by Google's reCAPTCHA. Privacy Policy and Terms of Service apply.